# Lysosomal protease-mediated APP degradation is pH-dependent, mutation-sensitive, and facilitates tau proteolysis

**Authors:** Caroline Ackley, Zoe Liau, Shruti Arya, Tara Antee, Emily Cheang, Giselle M. Knudsen, Courtney Lane-Donovan, Paul J. Sampognaro, Aimee W. Kao

PMC · DOI: 10.1186/s44477-025-00017-6 · Molecular Neurodegeneration Advances · 2026-01-19

## TL;DR

This study shows that APP is broken down in lysosomes, and this process is affected by pH and mutations, which may also help break down tau, a protein linked to Alzheimer's disease.

## Contribution

The study identifies pH-dependent and mutation-sensitive lysosomal protease cleavage sites in APP and reveals a novel link between APP and tau proteolysis.

## Key findings

- APP is enriched in the endo-lysosomal compartment and processed by multiple cathepsins.
- APP cleavage at specific sites is sensitive to pH and pathogenic variants E693G and E693Q.
- The sAPP domain enhances tau cleavage by cathepsin CTSG in vitro.

## Abstract

The accumulation and aggregation of amyloid beta (A\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\beta$$\end{document}β)—a peptide fragment derived from the proteolytic processing of amyloid precursor protein (APP)—is a central pathological feature of Alzheimer’s disease (AD) and a current target for disease-modifying therapies. Mutations in APP can also drive early-onset AD. While the roles of \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\alpha$$\end{document}α-, \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\beta$$\end{document}β-, and \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\gamma$$\end{document}γ-secretases and their respective cleavage sites in APP processing are well characterized, much less is understood about the routine degradation of APP within sub-cellular compartments like the lysosome.

We applied Multiplexed Substrate Profiling by Mass Spectrometry (MSP-MS) to map cleavage sites within APP that may be targeted by lysosomal proteases, also known as cathepsins. We then employed cell-based and in vitro assays to examine the degradation of both wild-type and mutant APP by these enzymes.

Our findings confirm that APP is enriched in the endo-lysosomal compartment, where it is processed by many cathepsins. Our experiments reveal that cleavages at several mapped APP sites are sensitive to both changes in pH and the presence of pathogenic variants E693G and E693Q. Additionally, we discovered that the large soluble domain of APP (sAPP) enhances tau cleavage by a specific cathepsin, CTSG, in vitro.

Collectively, these results underscore the importance of lysosomal processing of APP, identify a link between APP and tau, and suggest new avenues for exploring AD pathogenesis. They also highlight potential therapeutic targets related to the lysosomal function of APP and its impact on neurodegenerative diseases.

## Linked entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351]
- **Proteins:** MAPT (microtubule associated protein tau), CTSG (cathepsin G)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, CTSS (cathepsin S) [NCBI Gene 1520], APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, CTSG (cathepsin G) [NCBI Gene 1511] {aka CATG, CG}
- **Diseases:** AD (MESH:D000544), neurodegenerative diseases (MESH:D019636)
- **Mutations:** E693G, E693Q

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12886278/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12886278/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12886278/full.md

---
Source: https://tomesphere.com/paper/PMC12886278